CONTEXT: Patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency typically reach a final adult height well below their mid-parental target height. OBJECTIVE: The objective of this study was to examine whether GH alone or in combination with an LHRH analog (LHRHa) improved the final adult height in patients with CAH. DESIGN: The study was a nonrandomized prospective study. SETTING: The study was conducted at two university hospitals in New York City, NY. PARTICIPANTS: Thirty-four patients with CAH treated with GH participated in this study. Nineteen males and 15 females who were predicted to be more than 2 SD below their mid-parental target height or more than 2 SD below the population mean received GH until reaching final adult height. In addition to GH, 27 patients (16 males, 11 females) were also treated with an LHRHa. INTERVENTION: The mean duration of GH treatment was 5.6 ± 1.8 yr in males and 4.5 ± 1.6 yr in females. The mean duration of LHRHa therapy was 3.7 ± 1.7 yr for both sexes. MAIN OUTCOME MEASURES: The primary endpoint variables were final adult height, final height discrepancy, and gain in height. RESULTS: Males reached a significantly higher final adult height (172.0 ± 4.8 cm) than their initial predicted height (162.8 ± 7.7 cm) (P < 0.00001). Females also reached a significantly higher final adult height (162.2 ± 5.3 cm) than initially predicted (151.7 ± 5.2 cm) (P < 0.0000001). Mean gain in height was 9.2 ± 6.7 cm in males and 10.5 ± 3.7 cm in females. CONCLUSION: Our results indicate that GH alone or in combination with LHRHa improves final adult height in patients with CAH.
CONTEXT: Patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency typically reach a final adult height well below their mid-parental target height. OBJECTIVE: The objective of this study was to examine whether GH alone or in combination with an LHRH analog (LHRHa) improved the final adult height in patients with CAH. DESIGN: The study was a nonrandomized prospective study. SETTING: The study was conducted at two university hospitals in New York City, NY. PARTICIPANTS: Thirty-four patients with CAH treated with GH participated in this study. Nineteen males and 15 females who were predicted to be more than 2 SD below their mid-parental target height or more than 2 SD below the population mean received GH until reaching final adult height. In addition to GH, 27 patients (16 males, 11 females) were also treated with an LHRHa. INTERVENTION: The mean duration of GH treatment was 5.6 ± 1.8 yr in males and 4.5 ± 1.6 yr in females. The mean duration of LHRHa therapy was 3.7 ± 1.7 yr for both sexes. MAIN OUTCOME MEASURES: The primary endpoint variables were final adult height, final height discrepancy, and gain in height. RESULTS: Males reached a significantly higher final adult height (172.0 ± 4.8 cm) than their initial predicted height (162.8 ± 7.7 cm) (P < 0.00001). Females also reached a significantly higher final adult height (162.2 ± 5.3 cm) than initially predicted (151.7 ± 5.2 cm) (P < 0.0000001). Mean gain in height was 9.2 ± 6.7 cm in males and 10.5 ± 3.7 cm in females. CONCLUSION: Our results indicate that GH alone or in combination with LHRHa improves final adult height in patients with CAH.
Authors: Kalpana Muthusamy; Mohamed B Elamin; Galina Smushkin; Mohammad Hassan Murad; Julianna F Lampropulos; Khalid B Elamin; Nisrin O Abu Elnour; Juan F Gallegos-Orozco; Mitra M Fatourechi; Neera Agrwal; Melanie A Lane; Felipe N Albuquerque; Patricia J Erwin; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2010-09 Impact factor: 5.958
Authors: I Manoli; Ch Kanaka-Gantenbein; A Voutetakis; M Maniati-Christidi; C Dacou-Voutetakis Journal: Clin Endocrinol (Oxf) Date: 2002-11 Impact factor: 3.478
Authors: Dong Ho Lee; Sung Hye Kong; Han Na Jang; Chang Ho Ahn; Seung Gyun Lim; Young Ah Lee; Sang Wan Kim; Jung Hee Kim Journal: Arch Osteoporos Date: 2022-03-08 Impact factor: 2.617
Authors: Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White Journal: Endocr Rev Date: 2022-01-12 Impact factor: 19.871